Revance Therapeutics
Trial Pipeline
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines
NCT04259086
DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis
NCT03825315
Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)
NCT03617367
Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
NCT03137407
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
NCT02565732
Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
NCT01776606
A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
NCT01124552
Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00968942
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00888914
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 7 |
| Phase 3 | 2 |
What the Pipeline for Revance Therapeutics Shows
According to the ClinicalTrials.gov registry, Revance Therapeutics is linked to 9 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting — about 0% of the sponsor's indexed portfolio — and 9 are already marked complete, representing roughly 100% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Revance Therapeutics reports 2 late-stage studies (Phase 3 and Phase 4 combined) and 7 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Revance Therapeutics is Crow's Feet with 3 linked trials, and 7 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.